Jonathan McNeill - 18 Jan 2023 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Senior Vice President of Business Development
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol
DYN
Transactions as of
18 Jan 2023
Transactions value $
-$133,000
Form type
4
Filing time
23 Jan 2023, 07:27:05 UTC
Previous filing
11 Jan 2023
Next filing
15 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Options Exercise $7,300 +10,000 +14.79% $0.73* 77,600 18 Jan 2023 Direct F1
transaction DYN Common Stock Sale -$140,300 -10,000 -12.89% $14.03 67,600 18 Jan 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (right to buy) Options Exercise $0 -10,000 -12.73% $0 68,528 18 Jan 2023 Common Stock 10,000 $0.73 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is an inadvertent late filing due to an administrative error.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $14.00 to $14.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F4 The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter.

Remarks:

Senior Vice President of Business Development